Angiotensin System Blockers in Experimental NAFLD/MASLD: Is there a Preferential Pathway or Drug?
Mario Claudio Soares Sturzeneker, Flávia Cristina Colmenero, Jaqueline Meert Parlow, Isabela Hess Justus, Crisangela Cristin Consul, Gabriel dos Santos, Maíza Pellissari Migliorini, Karyn Maria Wenglarek & Thais de Lima da Silva · Journal of Advances in Medicine and Medical Research · 2024
Introduction: Nonalcoholic fatty liver disease (NAFLD), currently known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a persistent challenge in medical practice. Its global prevalence has progressively increased, with an estimated 30.1%. NAFLD has been a...
Open access
Research Article
10.9734/jammr/2024/v36i115635